Vladislav V Kovalik

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 5

Top Topics

Immune Response

Top Venues

Journal of comparative effectiveness research

This page only lists publications with an associated author ORCID identifier.

Publications

Roman V Drai, Alexander Y Mayorov, Tatiana L Karonova, Tatiana M Parfenova, Igor E Makarenko, Maxim A Magruk, Diana N Alpenidze, Vladislav V Kovalik, Bella R Zinnatulina, Irina V Grigorjeva, Alena T Andreeva
The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix ® 30 in Type 2 diabetes patients. Journal of comparative effectiveness research (2022)
Roman V Drai, Alexander Y Mayorov, Tatiana L Karonova, Tatiana M Parfenova, Igor E Makarenko, Maxim A Magruk, Diana N Alpenidze, Vladislav V Kovalik, Bella R Zinnatulina, Irina V Grigorjeva, Alena T Andreeva
The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix ® 30 in Type 2 diabetes patients. Journal of comparative effectiveness research 11 (18) (2022)
Roman V Drai, Alexander Y Mayorov, Tatiana L Karonova, Tatiana M Parfenova, Igor E Makarenko, Maxim A Magruk, Diana N Alpenidze, Vladislav V Kovalik, Bella R Zinnatulina, Irina V Grigorjeva, Alena T Andreeva
The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix ® 30 in Type 2 diabetes patients. Journal of comparative effectiveness research 11 (18) (2022)
Roman V Drai, Alexander Y Mayorov, Tatiana L Karonova, Tatiana M Parfenova, Igor E Makarenko, Maxim A Magruk, Diana N Alpenidze, Vladislav V Kovalik, Bella R Zinnatulina, Irina V Grigorjeva, Alena T Andreeva
The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix ® 30 in Type 2 diabetes patients. Journal of comparative effectiveness research 11 (18) (2022)
Roman V Drai, Alexander Y Mayorov, Tatiana L Karonova, Tatiana M Parfenova, Igor E Makarenko, Maxim A Magruk, Diana N Alpenidze, Vladislav V Kovalik, Bella R Zinnatulina, Irina V Grigorjeva, Alena T Andreeva
The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix ® 30 in Type 2 diabetes patients. Journal of comparative effectiveness research 11 (18) (2022)